You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMetolazone
Accession NumberDB00524  (APRD01109)
TypeSmall Molecule
GroupsApproved
DescriptionA quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. [PubChem]
Structure
Thumb
Synonyms
2-Methyl-3-O-tolyl-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone
7-Chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulfonamide
7-Chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-O-tolyl-6-quinazolinesulfonamide
Metolazon
Metolazona
Métolazone
Metolazonum
Zaroxolyn
External Identifiers
  • SR 720-22
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Metolazonetablet2.5 mg/1oralAvera Mc Kennan Hospital2015-04-16Not applicableUs
Metolazonetablet2.5 mg/1oralUpstate Pharma, LLC1973-11-27Not applicableUs
Metolazonetablet5 mg/1oralUpstate Pharma, LLC1973-11-27Not applicableUs
Metolazonetablet10 mg/1oralUpstate Pharma, LLC1973-11-27Not applicableUs
Zaroxolyntablet5 mg/1oralUNITHER Manufacturing LLC1973-11-272016-01-13Us
Zaroxolyntablet2.5 mg/1oralCarilion Materials Management1973-11-27Not applicableUs
Zaroxolyntablet2.5 mgoralSanofi Aventis Canada Inc1974-12-31Not applicableCanada
Zaroxolyntablet5 mgoralAventis Pharma Inc1974-12-312003-07-22Canada
Zaroxolyn Tab 10mgtablet10 mgoralRhone Poulenc Rorer Canada Inc.1974-12-311998-08-12Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Metolazonetablet5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2003-12-19Not applicableUs
Metolazonetablet5 mg/1oralEon Labs, Inc.2003-12-19Not applicableUs
Metolazonetablet2.5 mg/1oralCardinal Health2011-01-14Not applicableUs
Metolazonetablet5 mg/1oralMylan Institutional Inc.2005-02-01Not applicableUs
Metolazonetablet5 mg/1oralMylan Pharmaceuticals Inc.2004-10-19Not applicableUs
Metolazonetablet2.5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-01-18Not applicableUs
Metolazonetablet2.5 mg/1oralEon Labs, Inc.2003-12-19Not applicableUs
Metolazonetablet5 mg/1oralCardinal Health2011-01-14Not applicableUs
Metolazonetablet5 mg/1oralPhysicians Total Care, Inc.2004-04-27Not applicableUs
Metolazonetablet10 mg/1oralMylan Pharmaceuticals Inc.2004-10-19Not applicableUs
Metolazonetablet5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-01-18Not applicableUs
Metolazonetablet10 mg/1oralEon Labs, Inc.2003-12-19Not applicableUs
Metolazonetablet5 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2006-11-15Not applicableUs
Metolazonetablet2.5 mg/1oralPhysicians Total Care, Inc.2004-07-06Not applicableUs
Metolazonetablet2.5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2003-12-19Not applicableUs
Metolazonetablet2.5 mg/1oralMylan Institutional Inc.2005-04-15Not applicableUs
Metolazonetablet2.5 mg/1oralMylan Pharmaceuticals Inc.2004-01-06Not applicableUs
Metolazonetablet10 mg/1oralCarilion Materials Management2004-10-19Not applicableUs
Metolazonetablet10 mg/1oralPhysicians Total Care, Inc.2004-07-20Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DiuloNot Available
DiuremCipla
MetadureMicro Labs
MetenixIFET
MetolazNavana
MetoralDr. Reddy's
MetozCentaur
MetozoneYing Yuan
MykroxCelltech
PavedalPharma Investi
ZytanixZydus
Brand mixturesNot Available
SaltsNot Available
Categories
UNIITZ7V40X7VX
CAS number17560-51-9
WeightAverage: 365.835
Monoisotopic: 365.06008979
Chemical FormulaC16H16ClN3O3S
InChI KeyInChIKey=AQCHWTWZEMGIFD-UHFFFAOYSA-N
InChI
InChI=1S/C16H16ClN3O3S/c1-9-5-3-4-6-14(9)20-10(2)19-13-8-12(17)15(24(18,22)23)7-11(13)16(20)21/h3-8,10,19H,1-2H3,(H2,18,22,23)
IUPAC Name
7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide
SMILES
CC1NC2=CC(Cl)=C(C=C2C(=O)N1C1=CC=CC=C1C)S(N)(=O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as quinazolines. These are compounds containing a quinazoline moiety, which is made up of two fused six-member aromatic rings, a benzene ring and a pyrimidine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassNaphthyridines
Sub ClassQuinazolines
Direct ParentQuinazolines
Alternative Parents
Substituents
  • Quinazoline
  • Aminotoluene
  • Toluene
  • Secondary aliphatic/aromatic amine
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Vinylogous amide
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Tertiary amine
  • Lactam
  • Carboxamide group
  • Azacycle
  • Secondary amine
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class.
PharmacodynamicsMetolazone is a quinazoline diuretic, with properties generally similar to the thiazide diuretics. A proximal action of metolazone has been shown in humans by increased excretion of phosphate and magnesium ions and by a markedly increased fractional excretion of sodium in patients with severely compromised glomerular filtration. This action has been demonstrated in animals by micropuncture studies.
Mechanism of actionThe actions of metolazone result from interference with the renal tubular mechanism of electrolyte reabsorption. Metolazone acts primarily to inhibit sodium reabsorption at the cortical diluting site and to a lesser extent in the proximal convoluted tubule. Sodium and chloride ions are excreted in approximately equivalent amounts. The increased delivery of sodium to the distal tubular exchange site results in increased potassium excretion. Metolazone does not inhibit carbonic anhydrase. The antihypertensive mechanism of action of metolazone is not fully understood but is presumed to be related to its saluretic and diuretic properties.
Related Articles
AbsorptionPeak blood levels are obtained within 2 to 4 hours of oral administration. The rate and extent of absorption are formulation dependent.
Volume of distributionNot Available
Protein binding50-70% bound to erythrocytes, up to 33% bound to plasma proteins, 2-5% of the drug in circulation is unbound
Metabolism

Not substantially metabolized. 70-95% is excreted unchanged in urine via glomerular filtration and active tubular secretion. Undergoes enterohepatic recycling.

Route of eliminationMost of the drug is excreted in the unconverted form in the urine.
Half lifeApproximately 14 hours.
ClearanceNot Available
ToxicitySymptoms of overdose include difficulty breathing, dizziness, dizziness on standing up, drowsiness, fainting, irritation of the stomach and intestines, and lethargy leading to coma.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Metolazone Action PathwayDrug actionSMP00105
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9972
Blood Brain Barrier+0.5944
Caco-2 permeable-0.8957
P-glycoprotein substrateNon-substrate0.7578
P-glycoprotein inhibitor INon-inhibitor0.8113
P-glycoprotein inhibitor IINon-inhibitor0.5921
Renal organic cation transporterNon-inhibitor0.9223
CYP450 2C9 substrateNon-substrate0.6466
CYP450 2D6 substrateNon-substrate0.8279
CYP450 3A4 substrateNon-substrate0.579
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5788
Ames testNon AMES toxic0.8234
CarcinogenicityNon-carcinogens0.7193
BiodegradationNot ready biodegradable0.9961
Rat acute toxicity1.8955 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9922
hERG inhibition (predictor II)Non-inhibitor0.8735
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Gd searle llc
  • Mylan pharmaceuticals inc
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Ucb inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral10 mg/1
Tabletoral2.5 mg/1
Tabletoral5 mg/1
Tabletoral2.5 mg
Tabletoral5 mg
Tabletoral10 mg
Prices
Unit descriptionCostUnit
Zaroxolyn 10 mg tablet2.89USD tablet
Zaroxolyn 5 mg tablet2.75USD tablet
Metolazone 10 mg tablet1.8USD tablet
Zaroxolyn 2.5 mg tablet1.74USD tablet
Metolazone 5 mg tablet1.51USD tablet
Metolazone 2.5 mg tablet1.37USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point256 °CPhysProp
water solubility60.3 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.5Not Available
logS-3.78ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0407 mg/mLALOGPS
logP3.21ALOGPS
logP2.94ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)9.54ChemAxon
pKa (Strongest Basic)-1.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area92.5 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity94.59 m3·mol-1ChemAxon
Polarizability36.38 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Rosenberg J, Gustafsson F, Galatius S, Hildebrandt PR: Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature. Cardiovasc Drugs Ther. 2005 Aug;19(4):301-6. [PubMed:16189620 ]
External Links
ATC CodesC03BA08C03EA12
AHFS Codes
  • 40:28.24
PDB EntriesNot Available
FDA labelDownload (834 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
4-Androstenedione4-Androstenedione may increase the hypokalemic activities of Metolazone.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Metolazone.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Metolazone.
AcebutololMetolazone may increase the hypotensive activities of Acebutolol.
AceclofenacThe therapeutic efficacy of Metolazone can be decreased when used in combination with Aceclofenac.
AcetazolamideThe risk or severity of adverse effects can be increased when Metolazone is combined with Acetazolamide.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Metolazone.
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Metolazone is combined with Acetyldigitoxin.
Acetylsalicylic acidThe therapeutic efficacy of Metolazone can be decreased when used in combination with Acetylsalicylic acid.
AclidiniumThe serum concentration of Metolazone can be increased when it is combined with Aclidinium.
AdapaleneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Adapalene.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Metolazone.
AlclometasoneAlclometasone may increase the hypokalemic activities of Metolazone.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Metolazone.
AldosteroneAldosterone may increase the hypokalemic activities of Metolazone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Metolazone.
AlfuzosinAlfuzosin may increase the hypotensive activities of Metolazone.
AliskirenMetolazone may increase the hypotensive activities of Aliskiren.
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Metolazone.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Metolazone.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Metolazone.
AlprenololMetolazone may increase the hypotensive activities of Alprenolol.
AmbrisentanMetolazone may increase the hypotensive activities of Ambrisentan.
AmcinonideAmcinonide may increase the hypokalemic activities of Metolazone.
AmifostineMetolazone may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Metolazone is combined with Amiloride.
AmlodipineAmlodipine may increase the hypotensive activities of Metolazone.
AmobarbitalAmobarbital may increase the orthostatic hypotensive activities of Metolazone.
AmoxapineAmoxapine may increase the hyponatremic activities of Metolazone.
Amyl NitriteThe risk or severity of adverse effects can be increased when Metolazone is combined with Amyl Nitrite.
Anisotropine MethylbromideThe serum concentration of Metolazone can be increased when it is combined with Anisotropine Methylbromide.
AntipyrineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Antipyrine.
ApraclonidineThe risk or severity of adverse effects can be increased when Metolazone is combined with Apraclonidine.
ApremilastThe therapeutic efficacy of Metolazone can be decreased when used in combination with Apremilast.
ArbutamineArbutamine may increase the hypokalemic activities of Metolazone.
ArformoterolArformoterol may increase the hypokalemic activities of Metolazone.
AripiprazoleAripiprazole may increase the hypotensive activities of Metolazone.
AtenololAtenolol may increase the hypotensive activities of Metolazone.
Atracurium besylateThe serum concentration of Metolazone can be increased when it is combined with Atracurium besylate.
AtropineThe serum concentration of Metolazone can be increased when it is combined with Atropine.
AzapropazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Azapropazone.
AzelastineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Metolazone is combined with Azilsartan medoxomil.
BalsalazideThe therapeutic efficacy of Metolazone can be decreased when used in combination with Balsalazide.
BambuterolBambuterol may increase the hypokalemic activities of Metolazone.
BarbitalBarbital may increase the orthostatic hypotensive activities of Metolazone.
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Metolazone.
BenactyzineThe serum concentration of Metolazone can be increased when it is combined with Benactyzine.
BenazeprilMetolazone may increase the hypotensive activities of Benazepril.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Metolazone.
BenmoxinBenmoxin may increase the hypotensive activities of Metolazone.
BenoxaprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Benoxaprofen.
BenzatropineThe serum concentration of Metolazone can be increased when it is combined with Benzatropine.
BepridilMetolazone may increase the hypotensive activities of Bepridil.
BetamethasoneBetamethasone may increase the hypokalemic activities of Metolazone.
BetaxololBetaxolol may increase the hypotensive activities of Metolazone.
BethanidineBethanidine may increase the hypotensive activities of Metolazone.
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Metolazone.
BimatoprostMetolazone may increase the hypotensive activities of Bimatoprost.
BiperidenThe serum concentration of Metolazone can be increased when it is combined with Biperiden.
BisoprololMetolazone may increase the hypotensive activities of Bisoprolol.
BosentanMetolazone may increase the hypotensive activities of Bosentan.
BretyliumMetolazone may increase the hypotensive activities of Bretylium.
BrimonidineMetolazone may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Metolazone.
BromfenacThe therapeutic efficacy of Metolazone can be decreased when used in combination with Bromfenac.
BudesonideBudesonide may increase the hypokalemic activities of Metolazone.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Metolazone.
BumetanideThe risk or severity of adverse effects can be increased when Metolazone is combined with Bumetanide.
BupranololMetolazone may increase the hypotensive activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Metolazone.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Metolazone.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Metolazone.
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Metolazone.
CandesartanMetolazone may increase the hypotensive activities of Candesartan.
CandoxatrilMetolazone may increase the hypotensive activities of Candoxatril.
CaptoprilMetolazone may increase the hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Metolazone is combined with Carbamazepine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Metolazone.
CaroxazoneCaroxazone may increase the hypotensive activities of Metolazone.
CarprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Carprofen.
CarteololCarteolol may increase the hypotensive activities of Metolazone.
CarvedilolMetolazone may increase the hypotensive activities of Carvedilol.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Metolazone.
CelecoxibThe therapeutic efficacy of Metolazone can be decreased when used in combination with Celecoxib.
CeliprololMetolazone may increase the hypotensive activities of Celiprolol.
ChloroquineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Chloroquine.
ChlorothiazideMetolazone may increase the hypotensive activities of Chlorothiazide.
ChlorphenoxamineThe serum concentration of Metolazone can be increased when it is combined with Chlorphenoxamine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Metolazone.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Metolazone.
CholestyramineCholestyramine can cause a decrease in the absorption of Metolazone resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiclesonideCiclesonide may increase the hypokalemic activities of Metolazone.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Metolazone.
CilazaprilMetolazone may increase the hypotensive activities of Cilazapril.
CitalopramCitalopram may increase the hyponatremic activities of Metolazone.
ClenbuterolClenbuterol may increase the hypokalemic activities of Metolazone.
ClevidipineThe risk or severity of adverse effects can be increased when Metolazone is combined with Clevidipine.
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Metolazone.
ClocortoloneClocortolone may increase the hypokalemic activities of Metolazone.
ClomipramineClomipramine may increase the hyponatremic activities of Metolazone.
ClonidineMetolazone may increase the hypotensive activities of Clonidine.
ClonixinThe therapeutic efficacy of Metolazone can be decreased when used in combination with Clonixin.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Metolazone.
ColesevelamColesevelam can cause a decrease in the absorption of Metolazone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Metolazone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Metolazone.
CryptenamineMetolazone may increase the hypotensive activities of Cryptenamine.
CyclopentolateThe serum concentration of Metolazone can be increased when it is combined with Cyclopentolate.
CyclophosphamideThe risk or severity of adverse effects can be increased when Metolazone is combined with Cyclophosphamide.
CyclothiazideMetolazone may increase the hypotensive activities of Cyclothiazide.
D-LimoneneThe therapeutic efficacy of Metolazone can be decreased when used in combination with D-Limonene.
DapagliflozinThe risk or severity of adverse effects can be increased when Metolazone is combined with Dapagliflozin.
DapoxetineDapoxetine may increase the hyponatremic activities of Metolazone.
DarifenacinThe serum concentration of Metolazone can be increased when it is combined with Darifenacin.
DebrisoquinMetolazone may increase the hypotensive activities of Debrisoquin.
DehydroepiandrosteroneDehydroepiandrosterone may increase the hypokalemic activities of Metolazone.
dehydroepiandrosterone sulfatedehydroepiandrosterone sulfate may increase the hypokalemic activities of Metolazone.
DeserpidineMetolazone may increase the hypotensive activities of Deserpidine.
DeslanosideThe risk or severity of adverse effects can be increased when Metolazone is combined with Deslanoside.
DesloratadineThe serum concentration of Metolazone can be increased when it is combined with Desloratadine.
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Metolazone.
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Metolazone.
DexamethasoneDexamethasone may increase the hypokalemic activities of Metolazone.
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Metolazone.
DexetimideThe serum concentration of Metolazone can be increased when it is combined with Dexetimide.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Metolazone.
DexmedetomidineThe risk or severity of adverse effects can be increased when Metolazone is combined with Dexmedetomidine.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Metolazone.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Metolazone.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Metolazone.
DiazoxideDiazoxide may increase the hypotensive activities of Metolazone.
DiazoxideThe risk or severity of adverse effects can be increased when Metolazone is combined with Diazoxide.
DiclofenacThe therapeutic efficacy of Metolazone can be decreased when used in combination with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Metolazone is combined with Diclofenamide.
DicyclomineThe serum concentration of Metolazone can be increased when it is combined with Dicyclomine.
DiflorasoneDiflorasone may increase the hypokalemic activities of Metolazone.
DiflunisalThe therapeutic efficacy of Metolazone can be decreased when used in combination with Diflunisal.
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Metolazone.
DifluprednateDifluprednate may increase the hypokalemic activities of Metolazone.
DigitoxinThe risk or severity of adverse effects can be increased when Metolazone is combined with Digitoxin.
DigoxinThe risk or severity of adverse effects can be increased when Metolazone is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Metolazone.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Metolazone.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Metolazone.
DiltiazemDiltiazem may increase the hypotensive activities of Metolazone.
DinutuximabThe risk or severity of adverse effects can be increased when Metolazone is combined with Dinutuximab.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Metolazone.
DipivefrinDipivefrin may increase the hypokalemic activities of Metolazone.
DipyridamoleThe risk or severity of adverse effects can be increased when Metolazone is combined with Dipyridamole.
DobutamineDobutamine may increase the hypokalemic activities of Metolazone.
DofetilideMetolazone may increase the QTc-prolonging activities of Dofetilide.
DorzolamideMetolazone may increase the hypotensive activities of Dorzolamide.
DoxazosinMetolazone may increase the hypotensive activities of Doxazosin.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Metolazone.
DroxicamThe therapeutic efficacy of Metolazone can be decreased when used in combination with Droxicam.
DroxidopaDroxidopa may increase the hypokalemic activities of Metolazone.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Metolazone.
DuloxetineMetolazone may increase the orthostatic hypotensive activities of Duloxetine.
EfonidipineMetolazone may increase the hypotensive activities of Efonidipine.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Metolazone.
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Metolazone.
EnalaprilMetolazone may increase the hypotensive activities of Enalapril.
EnalaprilatMetolazone may increase the hypotensive activities of Enalaprilat.
EphedraEphedra may increase the hypokalemic activities of Metolazone.
EpinephrineEpinephrine may increase the hypokalemic activities of Metolazone.
EpirizoleThe therapeutic efficacy of Metolazone can be decreased when used in combination with Epirizole.
EplerenoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Eplerenone.
EpoprostenolMetolazone may increase the hypotensive activities of Epoprostenol.
EprosartanMetolazone may increase the hypotensive activities of Eprosartan.
EquileninEquilenin may increase the hypokalemic activities of Metolazone.
EquilinEquilin may increase the hypokalemic activities of Metolazone.
EscitalopramEscitalopram may increase the hyponatremic activities of Metolazone.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Metolazone.
EstroneEstrone may increase the hypokalemic activities of Metolazone.
Etacrynic acidThe risk or severity of adverse effects can be increased when Metolazone is combined with Etacrynic acid.
EtanerceptThe therapeutic efficacy of Metolazone can be decreased when used in combination with Etanercept.
EthanolEthanol may increase the orthostatic hypotensive activities of Metolazone.
EthopropazineThe serum concentration of Metolazone can be increased when it is combined with Ethopropazine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Metolazone.
EtodolacThe therapeutic efficacy of Metolazone can be decreased when used in combination with Etodolac.
EtofenamateThe therapeutic efficacy of Metolazone can be decreased when used in combination with Etofenamate.
EtoperidoneEtoperidone may increase the hyponatremic activities of Metolazone.
EtoricoxibThe therapeutic efficacy of Metolazone can be decreased when used in combination with Etoricoxib.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Metolazone.
Evening primrose oilThe therapeutic efficacy of Metolazone can be decreased when used in combination with Evening primrose oil.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Metolazone.
exisulindThe therapeutic efficacy of Metolazone can be decreased when used in combination with exisulind.
FelodipineMetolazone may increase the hypotensive activities of Felodipine.
FenbufenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Fenbufen.
FenfluramineFenfluramine may increase the hyponatremic activities of Metolazone.
FenoldopamMetolazone may increase the hypotensive activities of Fenoldopam.
FenoprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Fenoprofen.
FenoterolFenoterol may increase the hypokalemic activities of Metolazone.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Metolazone.
FesoterodineThe serum concentration of Metolazone can be increased when it is combined with Fesoterodine.
FloctafenineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Floctafenine.
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Metolazone.
FlumethasoneFlumethasone may increase the hypokalemic activities of Metolazone.
FlunisolideFlunisolide may increase the hypokalemic activities of Metolazone.
FlunixinThe therapeutic efficacy of Metolazone can be decreased when used in combination with Flunixin.
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Metolazone.
FluocinonideFluocinonide may increase the hypokalemic activities of Metolazone.
FluocortoloneFluocortolone may increase the hypokalemic activities of Metolazone.
FluorometholoneFluorometholone may increase the hypokalemic activities of Metolazone.
FluoxetineFluoxetine may increase the hyponatremic activities of Metolazone.
FluprednideneFluprednidene may increase the hypokalemic activities of Metolazone.
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Metolazone.
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Metolazone.
FlurbiprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Flurbiprofen.
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Metolazone.
Fluticasone PropionateFluticasone Propionate may increase the hypokalemic activities of Metolazone.
FluvoxamineFluvoxamine may increase the hyponatremic activities of Metolazone.
FormoterolFormoterol may increase the hypokalemic activities of Metolazone.
FosinoprilFosinopril may increase the hypotensive activities of Metolazone.
FurazolidoneFurazolidone may increase the hypotensive activities of Metolazone.
FurosemideThe risk or severity of adverse effects can be increased when Metolazone is combined with Furosemide.
Gallamine TriethiodideThe serum concentration of Metolazone can be increased when it is combined with Gallamine Triethiodide.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Metolazone.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Metolazone.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Metolazone.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Metolazone.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Metolazone.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Metolazone.
GlycopyrroniumThe serum concentration of Metolazone can be increased when it is combined with Glycopyrronium.
GuanabenzMetolazone may increase the hypotensive activities of Guanabenz.
GuanadrelGuanadrel may increase the hypotensive activities of Metolazone.
GuanethidineMetolazone may increase the hypotensive activities of Guanethidine.
GuanfacineMetolazone may increase the hypotensive activities of Guanfacine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Metolazone.
HexamethoniumMetolazone may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the orthostatic hypotensive activities of Metolazone.
HMPL-004The therapeutic efficacy of Metolazone can be decreased when used in combination with HMPL-004.
HomatropineThe serum concentration of Metolazone can be increased when it is combined with Homatropine.
HydracarbazineHydracarbazine may increase the hypotensive activities of Metolazone.
HydralazineMetolazone may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideMetolazone may increase the hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Metolazone.
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Metolazone.
HydroflumethiazideMetolazone may increase the hypotensive activities of Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Metolazone.
HyoscyamineThe serum concentration of Metolazone can be increased when it is combined with Hyoscyamine.
IbuprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Ibuprofen.
IbuproxamThe therapeutic efficacy of Metolazone can be decreased when used in combination with Ibuproxam.
IcatibantThe therapeutic efficacy of Metolazone can be decreased when used in combination with Icatibant.
IloprostIloprost may increase the hypotensive activities of Metolazone.
IndacaterolIndacaterol may increase the hypokalemic activities of Metolazone.
IndalpineIndalpine may increase the hyponatremic activities of Metolazone.
IndapamideMetolazone may increase the hypotensive activities of Indapamide.
IndenololMetolazone may increase the hypotensive activities of Indenolol.
IndomethacinThe therapeutic efficacy of Metolazone can be decreased when used in combination with Indomethacin.
IndoprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Indoprofen.
IndoraminMetolazone may increase the hypotensive activities of Indoramin.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Metolazone.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Metolazone.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Metolazone.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Metolazone.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Metolazone.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Metolazone.
Ipratropium bromideThe serum concentration of Metolazone can be increased when it is combined with Ipratropium bromide.
IproclozideIproclozide may increase the hypotensive activities of Metolazone.
IproniazidIproniazid may increase the hypotensive activities of Metolazone.
IrbesartanMetolazone may increase the hypotensive activities of Irbesartan.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Metolazone.
IsoetarineIsoetarine may increase the hypokalemic activities of Metolazone.
IsoprenalineIsoprenaline may increase the hypokalemic activities of Metolazone.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Metolazone is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Metolazone is combined with Isosorbide Mononitrate.
IsoxicamThe therapeutic efficacy of Metolazone can be decreased when used in combination with Isoxicam.
IsoxsuprineThe risk or severity of adverse effects can be increased when Metolazone is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Metolazone.
IvabradineMetolazone may increase the arrhythmogenic activities of Ivabradine.
KebuzoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Kebuzone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Metolazone.
KetoprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Ketoprofen.
KetorolacThe therapeutic efficacy of Metolazone can be decreased when used in combination with Ketorolac.
LabetalolMetolazone may increase the hypotensive activities of Labetalol.
LacidipineMetolazone may increase the hypotensive activities of Lacidipine.
LatanoprostMetolazone may increase the hypotensive activities of Latanoprost.
LeflunomideThe therapeutic efficacy of Metolazone can be decreased when used in combination with Leflunomide.
LercanidipineMetolazone may increase the hypotensive activities of Lercanidipine.
LevobunololThe risk or severity of adverse effects can be increased when Metolazone is combined with Levobunolol.
LevodopaMetolazone may increase the orthostatic hypotensive activities of Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Metolazone.
LevomilnacipranLevomilnacipran may increase the hyponatremic activities of Metolazone.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Metolazone.
LicoriceLicorice may increase the hypokalemic activities of Metolazone.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Metolazone.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Metolazone.
LisinoprilMetolazone may increase the hypotensive activities of Lisinopril.
LithiumMetolazone may decrease the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Metolazone.
LofexidineMetolazone may increase the hypotensive activities of Lofexidine.
LornoxicamThe therapeutic efficacy of Metolazone can be decreased when used in combination with Lornoxicam.
LosartanMetolazone may increase the hypotensive activities of Losartan.
LoxoprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Loxoprofen.
Lu AA21004Lu AA21004 may increase the hyponatremic activities of Metolazone.
LumiracoxibThe therapeutic efficacy of Metolazone can be decreased when used in combination with Lumiracoxib.
MacitentanMetolazone may increase the hypotensive activities of Macitentan.
Magnesium salicylateThe therapeutic efficacy of Metolazone can be decreased when used in combination with Magnesium salicylate.
ManidipineMetolazone may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Metolazone is combined with Mannitol.
MasoprocolThe therapeutic efficacy of Metolazone can be decreased when used in combination with Masoprocol.
MebanazineMebanazine may increase the hypotensive activities of Metolazone.
MecamylamineThe risk or severity of adverse effects can be increased when Metolazone is combined with Mecamylamine.
MecamylamineMecamylamine may increase the hypotensive activities of Metolazone.
Meclofenamic acidThe therapeutic efficacy of Metolazone can be decreased when used in combination with Meclofenamic acid.
MedrysoneMedrysone may increase the hypokalemic activities of Metolazone.
Mefenamic acidThe therapeutic efficacy of Metolazone can be decreased when used in combination with Mefenamic acid.
MelengestrolMelengestrol may increase the hypokalemic activities of Metolazone.
MeloxicamThe therapeutic efficacy of Metolazone can be decreased when used in combination with Meloxicam.
MesalazineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Mesalazine.
MetamizoleThe therapeutic efficacy of Metolazone can be decreased when used in combination with Metamizole.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Metolazone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Metolazone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Metolazone.
MethanthelineThe serum concentration of Metolazone can be increased when it is combined with Methantheline.
MethazolamideThe risk or severity of adverse effects can be increased when Metolazone is combined with Methazolamide.
MethohexitalMethohexital may increase the orthostatic hypotensive activities of Metolazone.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Metolazone.
MethyldopaMetolazone may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Metolazone.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Metolazone.
MethylphenobarbitalMethylphenobarbital may increase the orthostatic hypotensive activities of Metolazone.
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Metolazone.
MetipranololMetolazone may increase the hypotensive activities of Metipranolol.
MetixeneThe serum concentration of Metolazone can be increased when it is combined with Metixene.
MetoprololMetoprolol may increase the hypotensive activities of Metolazone.
MibefradilMetolazone may increase the hypotensive activities of Mibefradil.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Metolazone.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Metolazone.
MilnacipranMilnacipran may increase the hyponatremic activities of Metolazone.
MinaprineMinaprine may increase the hypotensive activities of Metolazone.
MinoxidilMinoxidil may increase the hypotensive activities of Metolazone.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Metolazone.
MoclobemideMoclobemide may increase the hypotensive activities of Metolazone.
MoexiprilMetolazone may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Metolazone.
MometasoneMometasone may increase the hypokalemic activities of Metolazone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Metolazone.
MoxonidineMetolazone may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe therapeutic efficacy of Metolazone can be decreased when used in combination with Mycophenolate mofetil.
Mycophenolic acidThe therapeutic efficacy of Metolazone can be decreased when used in combination with Mycophenolic acid.
N-butylscopolammonium bromideThe serum concentration of Metolazone can be increased when it is combined with N-butylscopolammonium bromide.
NabumetoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Nabumetone.
NadololMetolazone may increase the hypotensive activities of Nadolol.
NaftifineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Naftifine.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Metolazone.
NaproxenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Naproxen.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Metolazone.
NCX 4016The therapeutic efficacy of Metolazone can be decreased when used in combination with NCX 4016.
NebivololMetolazone may increase the hypotensive activities of Nebivolol.
NepafenacThe therapeutic efficacy of Metolazone can be decreased when used in combination with Nepafenac.
NesiritideThe risk or severity of adverse effects can be increased when Metolazone is combined with Nesiritide.
NialamideNialamide may increase the hypotensive activities of Metolazone.
NicardipineMetolazone may increase the hypotensive activities of Nicardipine.
NicorandilNicorandil may increase the hypotensive activities of Metolazone.
NifedipineThe risk or severity of adverse effects can be increased when Metolazone is combined with Nifedipine.
Niflumic AcidThe therapeutic efficacy of Metolazone can be decreased when used in combination with Niflumic Acid.
NiguldipineMetolazone may increase the hypotensive activities of Niguldipine.
NilvadipineMetolazone may increase the hypotensive activities of Nilvadipine.
NimesulideThe therapeutic efficacy of Metolazone can be decreased when used in combination with Nimesulide.
NimodipineNimodipine may increase the hypotensive activities of Metolazone.
NisoldipineNisoldipine may increase the hypotensive activities of Metolazone.
NitrendipineMetolazone may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Metolazone is combined with Nitroglycerin.
NitroprussideNitroprusside may increase the hypotensive activities of Metolazone.
NorepinephrineNorepinephrine may increase the hypokalemic activities of Metolazone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Metolazone.
NVA237The serum concentration of Metolazone can be increased when it is combined with NVA237.
ObinutuzumabMetolazone may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Metolazone.
OlanzapineOlanzapine may increase the hyponatremic activities of Metolazone.
OlmesartanOlmesartan may increase the hypotensive activities of Metolazone.
OlodaterolOlodaterol may increase the hypokalemic activities of Metolazone.
OlopatadineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Olopatadine.
OlsalazineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Olsalazine.
OmapatrilatMetolazone may increase the hypotensive activities of Omapatrilat.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Metolazone.
OrciprenalineOrciprenaline may increase the hypokalemic activities of Metolazone.
OrgoteinThe therapeutic efficacy of Metolazone can be decreased when used in combination with Orgotein.
OrphenadrineThe serum concentration of Metolazone can be increased when it is combined with Orphenadrine.
OuabainThe risk or severity of adverse effects can be increased when Metolazone is combined with Ouabain.
OxaprozinThe therapeutic efficacy of Metolazone can be decreased when used in combination with Oxaprozin.
OxcarbazepineThe risk or severity of adverse effects can be increased when Metolazone is combined with Oxcarbazepine.
OxprenololMetolazone may increase the hypotensive activities of Oxprenolol.
OxybutyninThe serum concentration of Metolazone can be increased when it is combined with Oxybutynin.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Metolazone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Metolazone.
OxyphenbutazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Oxyphenbutazone.
OxyphenoniumThe serum concentration of Metolazone can be increased when it is combined with Oxyphenonium.
PancuroniumThe serum concentration of Metolazone can be increased when it is combined with Pancuronium.
PapaverineThe risk or severity of adverse effects can be increased when Metolazone is combined with Papaverine.
ParamethasoneParamethasone may increase the hypokalemic activities of Metolazone.
ParecoxibThe therapeutic efficacy of Metolazone can be decreased when used in combination with Parecoxib.
PargylineMetolazone may increase the hypotensive activities of Pargyline.
ParoxetineParoxetine may increase the hyponatremic activities of Metolazone.
PenbutololMetolazone may increase the hypotensive activities of Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Metolazone.
PentobarbitalPentobarbital may increase the orthostatic hypotensive activities of Metolazone.
PentoliniumMetolazone may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Metolazone.
PerindoprilMetolazone may increase the hypotensive activities of Perindopril.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Metolazone.
PhenelzinePhenelzine may increase the hypotensive activities of Metolazone.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Metolazone.
PheniprazinePheniprazine may increase the hypotensive activities of Metolazone.
PhenobarbitalPhenobarbital may increase the orthostatic hypotensive activities of Metolazone.
PhenoxybenzamineMetolazone may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Metolazone.
PhentolamineMetolazone may increase the hypotensive activities of Phentolamine.
PhenylbutazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Phenylbutazone.
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Metolazone.
PimecrolimusThe therapeutic efficacy of Metolazone can be decreased when used in combination with Pimecrolimus.
PinacidilMetolazone may increase the hypotensive activities of Pinacidil.
PindololMetolazone may increase the hypotensive activities of Pindolol.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Metolazone.
PipecuroniumThe serum concentration of Metolazone can be increased when it is combined with Pipecuronium.
PirbuterolPirbuterol may increase the hypokalemic activities of Metolazone.
PirenzepineThe serum concentration of Metolazone can be increased when it is combined with Pirenzepine.
PirfenidoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Pirfenidone.
PirlindolePirlindole may increase the hypotensive activities of Metolazone.
PiroxicamThe therapeutic efficacy of Metolazone can be decreased when used in combination with Piroxicam.
PivhydrazinePivhydrazine may increase the hypotensive activities of Metolazone.
PolythiazideMetolazone may increase the hypotensive activities of Polythiazide.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Metolazone.
PrazosinPrazosin may increase the hypotensive activities of Metolazone.
PrednicarbatePrednicarbate may increase the hypokalemic activities of Metolazone.
PrednisolonePrednisolone may increase the hypokalemic activities of Metolazone.
PrednisonePrednisone may increase the hypokalemic activities of Metolazone.
PregnenolonePregnenolone may increase the hypokalemic activities of Metolazone.
PrimidonePrimidone may increase the orthostatic hypotensive activities of Metolazone.
ProcaterolProcaterol may increase the hypokalemic activities of Metolazone.
ProcyclidineThe serum concentration of Metolazone can be increased when it is combined with Procyclidine.
PropacetamolThe therapeutic efficacy of Metolazone can be decreased when used in combination with Propacetamol.
PropanthelineThe serum concentration of Metolazone can be increased when it is combined with Propantheline.
PropranololMetolazone may increase the hypotensive activities of Propranolol.
PTC299The therapeutic efficacy of Metolazone can be decreased when used in combination with PTC299.
QuetiapineThe risk or severity of adverse effects can be increased when Metolazone is combined with Quetiapine.
QuinaprilMetolazone may increase the hypotensive activities of Quinapril.
QuinidineThe serum concentration of Metolazone can be increased when it is combined with Quinidine.
QuinineQuinine may increase the hypotensive activities of Metolazone.
RamiprilRamipril may increase the hypotensive activities of Metolazone.
RasagilineRasagiline may increase the hypotensive activities of Metolazone.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Metolazone.
RemikirenRemikiren may increase the hypotensive activities of Metolazone.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Metolazone.
RescinnamineMetolazone may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Metolazone.
ResveratrolThe therapeutic efficacy of Metolazone can be decreased when used in combination with Resveratrol.
RimexoloneRimexolone may increase the hypokalemic activities of Metolazone.
RiociguatMetolazone may increase the hypotensive activities of Riociguat.
RisperidoneMetolazone may increase the hypotensive activities of Risperidone.
RitodrineRitodrine may increase the hypokalemic activities of Metolazone.
RituximabMetolazone may increase the hypotensive activities of Rituximab.
RofecoxibThe therapeutic efficacy of Metolazone can be decreased when used in combination with Rofecoxib.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Metolazone.
SafrazineSafrazine may increase the hypotensive activities of Metolazone.
SalbutamolSalbutamol may increase the hypokalemic activities of Metolazone.
SalicylamideThe therapeutic efficacy of Metolazone can be decreased when used in combination with Salicylamide.
Salicylic acidThe therapeutic efficacy of Metolazone can be decreased when used in combination with Salicylic acid.
SalmeterolSalmeterol may increase the hypokalemic activities of Metolazone.
SalsalateThe therapeutic efficacy of Metolazone can be decreased when used in combination with Salsalate.
SaprisartanMetolazone may increase the hypotensive activities of Saprisartan.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Metolazone.
ScopolamineThe serum concentration of Metolazone can be increased when it is combined with Scopolamine.
Scopolamine butylbromideThe serum concentration of Metolazone can be increased when it is combined with Scopolamine butylbromide.
SecobarbitalSecobarbital may increase the orthostatic hypotensive activities of Metolazone.
SelegilineSelegiline may increase the hypotensive activities of Metolazone.
SelexipagMetolazone may increase the hypotensive activities of Selexipag.
SeratrodastThe therapeutic efficacy of Metolazone can be decreased when used in combination with Seratrodast.
SertralineSertraline may increase the hyponatremic activities of Metolazone.
SildenafilSildenafil may increase the antihypertensive activities of Metolazone.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Metolazone.
SitaxentanMetolazone may increase the hypotensive activities of Sitaxentan.
SolifenacinThe serum concentration of Metolazone can be increased when it is combined with Solifenacin.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Metolazone.
SpiraprilMetolazone may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Metolazone.
SRT501The therapeutic efficacy of Metolazone can be decreased when used in combination with SRT501.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Metolazone.
SulfasalazineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Sulfasalazine.
SulindacThe therapeutic efficacy of Metolazone can be decreased when used in combination with Sulindac.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Metolazone.
SulpirideThe risk or severity of adverse effects can be increased when Metolazone is combined with Sulpiride.
SuprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Suprofen.
TadalafilTadalafil may increase the antihypertensive activities of Metolazone.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Metolazone.
TelmisartanMetolazone may increase the hypotensive activities of Telmisartan.
TemocaprilMetolazone may increase the hypotensive activities of Temocapril.
TenoxicamThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tenoxicam.
TepoxalinThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tepoxalin.
TerazosinThe risk or severity of adverse effects can be increased when Metolazone is combined with Terazosin.
TerbutalineTerbutaline may increase the hypokalemic activities of Metolazone.
TeriflunomideThe therapeutic efficacy of Metolazone can be decreased when used in combination with Teriflunomide.
TerlipressinMetolazone may increase the hypotensive activities of Terlipressin.
ThiamylalThiamylal may increase the orthostatic hypotensive activities of Metolazone.
ThiopentalThiopental may increase the orthostatic hypotensive activities of Metolazone.
Tiaprofenic acidThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tiaprofenic acid.
TiboloneMetolazone may increase the hypotensive activities of Tibolone.
TicrynafenMetolazone may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Metolazone.
TiotropiumThe serum concentration of Metolazone can be increased when it is combined with Tiotropium.
TixocortolTixocortol may increase the hypokalemic activities of Metolazone.
TizanidineThe risk or severity of adverse effects can be increased when Metolazone is combined with Tizanidine.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Metolazone.
TolazolineMetolazone may increase the hypotensive activities of Tolazoline.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Metolazone.
Tolfenamic AcidThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tolfenamic Acid.
TolmetinThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tolmetin.
ToloxatoneToloxatone may increase the hypotensive activities of Metolazone.
TolterodineThe serum concentration of Metolazone can be increased when it is combined with Tolterodine.
TopiramateMetolazone may increase the hypokalemic activities of Topiramate.
TorasemideTorasemide may increase the hypotensive activities of Metolazone.
ToremifeneMetolazone may increase the hypercalcemic activities of Toremifene.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Metolazone.
TrandolaprilTrandolapril may increase the hypotensive activities of Metolazone.
TranilastThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Metolazone.
TranylcypromineTranylcypromine may increase the hypotensive activities of Metolazone.
TravoprostTravoprost may increase the hypotensive activities of Metolazone.
TrazodoneTrazodone may increase the hyponatremic activities of Metolazone.
TreprostinilTreprostinil may increase the hypotensive activities of Metolazone.
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Metolazone.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Metolazone.
TrichlormethiazideMetolazone may increase the hypotensive activities of Trichlormethiazide.
TrihexyphenidylThe serum concentration of Metolazone can be increased when it is combined with Trihexyphenidyl.
TrimazosinMetolazone may increase the hypotensive activities of Trimazosin.
TrimethaphanMetolazone may increase the hypotensive activities of Trimethaphan.
Trisalicylate-cholineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Trisalicylate-choline.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Metolazone.
TropicamideThe serum concentration of Metolazone can be increased when it is combined with Tropicamide.
TrospiumThe serum concentration of Metolazone can be increased when it is combined with Trospium.
TubocurarineThe serum concentration of Metolazone can be increased when it is combined with Tubocurarine.
UdenafilUdenafil may increase the antihypertensive activities of Metolazone.
UmeclidiniumThe serum concentration of Metolazone can be increased when it is combined with Umeclidinium.
UnoprostoneMetolazone may increase the hypotensive activities of Unoprostone.
ValdecoxibThe therapeutic efficacy of Metolazone can be decreased when used in combination with Valdecoxib.
ValsartanValsartan may increase the hypotensive activities of Metolazone.
VardenafilVardenafil may increase the antihypertensive activities of Metolazone.
VecuroniumThe serum concentration of Metolazone can be increased when it is combined with Vecuronium.
VerapamilThe risk or severity of adverse effects can be increased when Metolazone is combined with Verapamil.
VilanterolVilanterol may increase the hypokalemic activities of Metolazone.
VilazodoneVilazodone may increase the hyponatremic activities of Metolazone.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Metolazone.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Metolazone.
VortioxetineVortioxetine may increase the hyponatremic activities of Metolazone.
XylometazolineMetolazone may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Metolazone.
ZaltoprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Zaltoprofen.
ZileutonThe therapeutic efficacy of Metolazone can be decreased when used in combination with Zileuton.
ZimelidineZimelidine may increase the hyponatremic activities of Metolazone.
ZomepiracThe therapeutic efficacy of Metolazone can be decreased when used in combination with Zomepirac.
Food Interactions
  • Take with food to reduce gastric irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Key mediator of sodium and chloride reabsorption in this nephron segment, accounting for a significant fraction of renal sodium reabsorption.
Gene Name:
SLC12A3
Uniprot ID:
P55017
Molecular Weight:
113138.04 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23